Record-setting scale: Researchers simulated protein-ligand complexes up to 12,635 atoms, the largest hybrid quantum-classical chemistry calculation for a biologically relevant system. Hybrid workflow: ...

How reorganizing existing drugs and vaccine components can dramatically alter their potency, selectivity, and even their ...

Orchestra BioMed (Nasdaq:OBIO) announced today that it secured $35 million in total funding through partnerships with Medtronic and Ligand.

$15 million payment fulfills previously scheduled tranche under royalty-based financing agreement, bringing total capital received from Ligand to $40 million to date in exchange for tiered royalty ...

Decoy Therapeutics Inc. (Nasdaq: DCOY), a preclinical-stage biotechnology company pioneering Designable Multi-Antivirals (D-MAVs ™), a new category of antivirals engineered to target shared viral ...

Transaction expands Ligand's royalty portfolio to more than 200 assets and adds seven new commercial products Bolsters and diversifies Ligand's long-term compounding growth, adding a complementary por ...

Transaction expands Ligand’s royalty portfolio to more than 200 assets and adds seven new commercial productsBolsters and diversifies Ligand’s ...

Ligands may be small molecules, but their impact on biology is massive—from stabilizing protein structures to driving drug discovery breakthroughs. Understanding how they bind and interact reveals the ...

COMMERCE CITY, Colo. (KDVR) — Colorado has become the first state to pass a law banning an arrest based solely on a colorimetric drug test, a common tool used by police to identify suspected narcotics ...

Sir Demis Hassabis has long had an ambitious plan: to develop artificial-intelligence models capable of curing all diseases. His journey towards realising it has been a circuitous one—few career ...

5,000 shares were sold on March 4, 2026, through an option exercise and immediate disposition, yielding a transaction value of ~$1.03 million at around $206.35 per share. The sale represented 11.94% ...

The transaction represented 12.70% of his direct common stock holdings, reducing his position from 24,067 to 21,010 shares. This sale was executed directly, with no indirect or trust entities involved ...